A Study of ORX142 in Healthy Adult Subjects, Including Subjects 18 to 80 Years of Age
A Randomized, Double-blind, Sponsor-open, Placebo-controlled Study of the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single and Multiple Ascending Doses of ORX142 in Healthy Adults, Single Doses of ORX142 in Healthy Older Adults, and a Single Dose Crossover, Proof-of-concept Study of ORX142 in Acutely Sleep-deprived Healthy Subjects
Centessa Pharmaceuticals (UK) Limited
208 participants
Jun 30, 2025
INTERVENTIONAL
Conditions
Summary
Characterize the safety, tolerability and pharmacokinetics of ORX142 following single and multiple doses.
Eligibility
Inclusion Criteria5
- Healthy males or females as determined by assessments at the Screening Visit.
- For Parts A, B, C, and E:
- a. Participants must be at least 18 years of age and no more than 55 years of age at the Screening
- For Part D:
- a .Participants must be at least 60 years of age and no more than 80 years of age at the Screening
Exclusion Criteria3
- Presence of significant cardiac, pulmonary, gastrointestinal, hepatic, renal, hematological, malignancy, endocrine, neurological, or psychiatric disease, as determined by medical history, physical examination, and screening investigations.
- History of seizure disorder, any other condition that increases the risk of seizure
- Has a clinically significant sleep disorder, including insomnia or sleep apnea.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
ORX142 Tablets
Placebo Tablets
Locations(3)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07082829